Menu
Cart 0

New Meningitis Vaccine

Posted by Stuart Rose on

Until now, travelers could not be protected against meniningitis B. Vaccines (Menactra, Menomune) have been available only against serogroups C, Y, and W135. Until recently, there were no serogroup B meningococcal vaccines licensed for use in the United States.

On October 29, 2014, the Food and Drug Administration (FDA) licensed the first serogroup B meningococcal vaccine (Trumenba®). FDA approved this vaccine for use in people 10-25 years of age as a 3-dose series. On January 23, 2015, FDA licensed a second serogroup B meningococcal vaccine (Bexsero®). FDA approved this vaccine for use in people 10-25 years of age as a 2-dose series. While there is no routine recommendation for serogroup B meningococcal vaccines at this time, physicians can use these vaccines for people 10-25 years of age consistent with the labeled indication.


Share this post



← Older Post Newer Post →


Leave a comment